SHR-1316、Chemotherapeutic
Phase 3Small molecule
SHR-1316、Chemotherapeutic is one of 7 small molecule programs targeting Resectable NSCLC. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Resectable NSCLC
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPhase 2
Fabhalta
RegeneronPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
QL1706
Qilu Pharmaceutical Co., Ltd.Phase 2
Platinum Doublet
RegeneronPhase 2
SHR-1316、Chemotherapeutic
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Immunochemotherapy Combined With Antiangiogenic
IIRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-1316、Chemotherapeutic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details